BioAge raises $170M for combination therapy with Zepbound

Illustration:STAT;Source:EliLilly/APACaliforniabiotechdevelopingacombinationtherapywiththeobesitydru AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha




Wikipedia

author：Wikipedia    Page View：4567
The Chamber of Commerce in downtown Washington, DC.
The U.S. Chamber of Commerce sued to stop a new Medicare drug price negotiation program from going into effect. Adobe

WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday over whether drugmakers have enough say in Medicare’s new drug price negotiation program, in the first oral arguments in a lawsuit challenging the new law.

The two sides debated two questions: whether the Chamber of Commerce would be sufficiently injured by the law to file a lawsuit, and whether the negotiation program was a violation of drugmakers’ due process rights.

advertisement

The hearing was held in the U.S. District Court for the Southern District of Ohio, and Judge Michael Newman, a Trump nominee, presided. Newman didn’t ask any questions of the attorneys, so the hearing didn’t provide any hints about which way he might be leaning on the issues.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Medicare threatens to cut off funding for HCA's Mission hospital
Next article： In Memoriam: Notable people who died in 2023